Avivagen Patent Applications Allowed in Indonesia and Mexico

OTTAWA, ONTARIO, April 4, 2013 - Avivagen Inc. (TSXV: VIV), a wellness company committed to developing products that support the health of animals and the people who care for them, is pleased to announce that its patent application "Compositions and methods for promoting weight gain and feed conversion" has been Allowed by the Patent Offices of Indonesia and Mexico.

The Allowances relate to claims for oxidized carotenoids, including OxC-beta, as non-antibiotic alternatives in commercial animal feeds - for species such as cattle, poultry, sheep, swine, crustaceans and fish. Indonesia is the world's eighth largest producer of chicken eggs and chicken meat, and it is a significant contributor to world tilapia and shrimp output. In turn, Mexico is the world's fourth largest producer of chicken eggs and meat, and the fourth largest pork producer in the Americas, after the U.S., Brazil and Canada.

Avivagen has identified its technology as a non-antibiotic alternative for promoting growth and efficient feed conversion in food-animals. In many countries, the majority of antibiotics are used in animal feeds for such non-therapeutic purposes. As asserted by the Ontario Medical Association on March 20, 2013, there is growing concern that this high-volume use of antibiotics in animals promotes the development of the antibiotic-resistant microorganisms that are a threat to human health.

In response to this situation, there is increasing pressure to restrict the use of antibiotics in animal feed and an un-met need for safe and effective non-antibiotic agents for use in food-animals. Because feed is a large production cost, a non-antibiotic product that can improve feed conversion and enhance growth is of potential value to producers.

Similar claims have been allowed or granted for this patent family in Canada, the United States, Australia, Russia and South Africa. The feeding claims are pending in other jurisdictions, including Europe, Asia and South America. Other patent families provide further protections to Avivagen's technologies.

About Avivagen

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker "VIV." The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and food animals by taking advantage of natural mechanisms for maintaining optimal health. Avivagen's targeted markets include Pet Wellness and Livestock Productivity.

The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - In Ottawa (Chemistry) and Charlottetown, Prince Edward Island (Nutriscience).

More information can be found at www.avivagen.com.

About OxC-Beta

Avivagen's proprietary and patent-protected technology enhances the body's own systems to maintain and improve health, particularly by supporting immune function. Avivagen's commercial technology is Fully-Oxidized Beta-Carotene (OxC-beta).

OxC-Beta compounds occur naturally in vegetation but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.

Research results indicate OxC-Beta helps support immune function, which can result in meaningful overall health improvements. In pets, improvements are seen in overall vitality and energy, skin, coat and gastrointestinal wellness. Food Animal benefits include healthier growth, better utilization of feed and decreased mortality.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Cameron Groome

CEO and President, Avivagen Inc.

Phone: [phone]

[e-mail]